Phase 1b data demonstrated 100% clinical response and promising signals regarding the efficacy of PALI-2108 in ulcerative colitis (UC) using FDA-defined endpoints Biomarker analyses showed ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results